Cardiomyopathy is not the same thing as heart failure, but the two are closely related. Cardiomyopathy is a disease of the heart muscle itself, while heart failure is a broader syndrome where the heart can no longer pump enough blood to meet the body’s needs. Cardiomyopathy is one of many conditions that can lead to heart failure, and it’s among the most common causes.
How They Relate to Each Other
Think of it this way: cardiomyopathy is a structural problem, and heart failure is the functional result. Heart failure is not a single disease. It’s a chronic, progressive condition that can be the final common pathway from a number of different cardiac disorders. Coronary artery disease, long-standing high blood pressure, valve disorders, and cardiomyopathy can all end up at the same destination. Cardiomyopathy just means “disease of the heart muscle,” and when that muscle becomes damaged or weakened enough, the heart eventually fails to keep up with demand.
Not everyone with cardiomyopathy has heart failure. Some people carry a genetic mutation linked to cardiomyopathy but show no structural changes on imaging yet. Others have visible thickening or enlargement of the heart wall but feel no symptoms. These are considered pre-heart-failure stages. The progression from a diseased muscle to full-blown heart failure can take years, and in some cases, with treatment, it can be slowed significantly or even partially reversed.
What Happens Inside the Heart
When the heart muscle is diseased, several things go wrong at the cellular level. The muscle cells lose their ability to contract normally, partly because calcium (which triggers each heartbeat’s squeeze) doesn’t cycle through the cells the way it should. The heart also struggles to relax properly between beats, which means it can’t fill with enough blood before the next contraction.
At first, the body compensates. Heart rate increases, blood vessels tighten to maintain pressure, and hormonal systems kick in to retain fluid and boost output. These workarounds help for a while, but they eventually backfire. The extra strain causes the heart chambers to stretch and remodel into shapes that pump less efficiently. Valves that once closed tightly start to leak because the chambers around them have grown too large. The hormonal signals that were meant to help start damaging the muscle further. Eventually, these compensatory mechanisms become overwhelmed and the heart fails.
Types of Cardiomyopathy and Heart Failure Risk
The three main types of cardiomyopathy each carry different risks and follow different paths toward heart failure.
Dilated cardiomyopathy is the most common form and the most directly linked to heart failure. The heart chambers enlarge and the walls thin, reducing the heart’s pumping power. As the ventricles stretch, the mitral and tricuspid valves no longer close properly, which drops the pumping efficiency even further. The prognosis can be serious: roughly half of patients with dilated cardiomyopathy die within five years of diagnosis, with outcomes worst for those who already have symptoms at rest or who can’t exercise.
Hypertrophic cardiomyopathy involves abnormal thickening of the heart wall, typically the left ventricle. Diagnosis in adults requires wall thickness of 15 mm or more on imaging, with no other explanation for the thickening. The thickened muscle becomes stiff, making it harder for the heart to relax and fill between beats. This can eventually lead to heart failure even when the pumping strength looks normal on tests.
Restrictive cardiomyopathy is the rarest type. The heart walls become rigid, limiting how much they can stretch to accept incoming blood. The pumping action may remain relatively normal, but the heart can’t fill adequately, which leads to the same downstream problem: not enough blood reaching the body.
When Symptoms Appear
Cardiomyopathy often exists silently before any symptoms develop. The heart can have measurable structural changes on an echocardiogram while you feel perfectly fine. This is sometimes called pre-heart-failure or Stage B heart failure, where the heart isn’t working well or is structurally abnormal but hasn’t produced noticeable symptoms yet. Even earlier, Stage A applies to people who have no structural changes but are at high risk, such as those with a family history of cardiomyopathy.
Once the heart’s compensatory mechanisms start failing, symptoms appear. The hallmark signs of heart failure include shortness of breath during mild exertion or while lying flat, fatigue that limits daily activity, swelling in the legs or ankles from fluid retention, and a persistent cough. These symptoms reflect the heart’s inability to move blood efficiently, not the cardiomyopathy itself. You can have cardiomyopathy for years without any of these symptoms if the heart is still compensating.
Genetics Play a Larger Role Than Many Expect
Many cases of cardiomyopathy have a genetic component, and certain mutations predict a faster or more severe path toward heart failure. Mutations in the gene for titin, a giant protein that acts like a molecular spring in heart muscle, are among the most common causes of dilated cardiomyopathy. Men with these mutations tend to develop more severe pumping problems than women.
A specific deletion in the phospholamban gene has been linked to early-onset cardiomyopathy with dangerous heart rhythm disturbances. In South Asian populations, roughly 4% carry a deletion in the MYBPC3 gene that increases the risk of both cardiomyopathy and heart failure, and worsens outcomes after a heart attack. People who carry more than one cardiomyopathy-related mutation often develop disease earlier and progress faster. Genetic testing can identify some of these variants before the heart shows any visible changes, placing a person in that preclinical, genotype-positive but phenotype-negative category.
How Treatment Differs
Because cardiomyopathy and heart failure are different problems, they sometimes require different treatment strategies, though there’s significant overlap. Heart failure treatment focuses on managing the syndrome: reducing fluid overload, lowering the workload on the heart, and slowing the harmful hormonal cycles that accelerate damage. Cardiomyopathy treatment, on the other hand, sometimes targets the root cause of the muscle disease.
A clear example is tachycardia-induced cardiomyopathy, where a persistently fast or irregular heart rhythm damages the heart muscle over time. The primary goal is to fix the rhythm problem, either by slowing the heart rate with medication, restoring a normal rhythm with electrical cardioversion, or destroying the source of the abnormal rhythm with a catheter-based procedure. Once the rhythm is corrected, the heart muscle can sometimes recover substantially. But while the rhythm issue is being addressed, standard heart failure treatment still needs to run in parallel to manage symptoms and prevent further deterioration.
For patients whose pumping function drops below 35% despite medication, device-based therapies become relevant. Implantable defibrillators can protect against sudden cardiac death from dangerous rhythms, which are a particular risk in cardiomyopathy. Cardiac resynchronization therapy, a specialized pacemaker, can improve pumping efficiency when the heart’s electrical system is also out of sync. In the most advanced cases, a heart transplant or mechanical pump may be the only remaining option.
Ejection Fraction Ties Them Together
Ejection fraction, the percentage of blood the heart pumps out with each beat, is the single number that most often bridges the gap between a cardiomyopathy diagnosis and a heart failure classification. A normal ejection fraction is typically 55% to 70%. Heart failure with reduced ejection fraction means the number has dropped below 40%. There’s also a middle category, sometimes called heart failure with mildly reduced ejection fraction, for values between 40% and 49%. And some people develop heart failure with a preserved ejection fraction, where the number looks normal but the heart is too stiff to fill properly. This last type is particularly common in hypertrophic and restrictive cardiomyopathy.
Ejection fraction matters because it determines which treatments are offered and how aggressively the condition is managed. Most of the major clinical trials for heart failure medications enrolled patients with ejection fractions at or below 35%, so that threshold often serves as a decision point for adding medications, implanting devices, or referring for advanced therapies. If your ejection fraction remains at or below 35% despite optimal treatment, referral for a defibrillator or transplant evaluation typically follows.